证券代码：600201 证券简称：生物股份 公告编号：临2025-034 金宇生物技术股份有限公司 关于转让投资基金份额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 金宇生物技术股份有限公司（以下简称"公司"）于 2015 年 10 月与其他合伙 人共同投资北京中技华科创业投资合伙企业（有限合伙）（以下简称"基金"或"中 技华科"）。基金认缴出资总额为 5.10 亿元，公司作为有限合伙人参与投资，认缴 出资金额 2 亿元，占其总规模的 39.2157%。 根据公司整体投资规划安排，公司与北京金陵华瑞咨询合伙企业（有限合伙） （以下简称"金陵华瑞"）签署了《财产份额转让协议》，将其持有的中技华科的 26.4706%的财产份额转让给金陵华瑞，转让价款为 13,500 万元。本次基金投资份 额转让完成后，公司持有基金份额 6,500 万份。 本次交易不构成关联交易，也不构成《上市公司重大资产重组管理办法》规定 的重大资产重组。根据《上海证券交易所股票上市规则》及《公司章程》等相关规 定，本次转让基金份额事项无需提交董事会审 ...

Core Viewpoint - The company announced the transfer of a 26.4706% stake in a venture capital partnership for a total consideration of 135 million yuan [1] Group 1 - The company will transfer its stake in Beijing Zhongji Huake Venture Capital Partnership to Beijing Jinling Huarui Consulting Partnership [1] - The transfer price is set at 135 million yuan [1] - After the transfer, the company will still hold 65 million shares in the fund [1]

Core Points - The article outlines the implementation details of the Audit Committee established by Jiangsu Sihuan Bioengineering Co., Ltd. to enhance the decision-making function of the board and ensure effective supervision of the management team [2][3] Group 1: General Provisions - The Audit Committee is a specialized working body set up by the board of directors to exercise the powers of the supervisory board as stipulated in the Company Law [2] - The committee is responsible for reviewing financial information, supervising internal and external audits, and evaluating internal controls [2][3] Group 2: Composition of the Committee - The Audit Committee consists of three directors, including two independent directors, with an independent director who is a financial professional serving as the convener [3][4] - The committee members are nominated by the chairman or a majority of independent directors and elected by the board [3][4] Group 3: Responsibilities and Authority - The main responsibilities include reviewing financial reports, supervising external and internal audits, and ensuring compliance with laws and regulations [4][5] - The committee must approve significant financial disclosures and the hiring or dismissal of external auditors before submission to the board [4][5] Group 4: Decision-Making Procedures - The Audit Department prepares written materials for the committee's decision-making, including financial reports and audit findings [7][8] - Regular meetings are held at least quarterly, with provisions for emergency meetings as needed [8][9] Group 5: Meeting Rules - Meetings require the presence of at least two-thirds of the committee members to be valid, and decisions are made by a majority vote [8][9] - The committee may invite external experts for professional opinions if necessary [9] Group 6: Supplementary Provisions - The implementation details take effect upon approval by the board and are subject to relevant national laws and regulations [10]

股 票 代 码 ： 000518 股 票 简 称 ： *ST 四 环 公 告 编 号 ： 临 -2025-35 号 江苏四环生物股份有限公司 第十届董事会第十三次会议决议公告 江苏四环生物股份有限公司（以下简称"公司"）于 2025 年 5 月 12 日在公 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 司会议室以现场结合通讯的方式召开了第十届董事会第十二次会议。本公司于 记载、误导性陈述或重大遗漏。 江苏四环生物股份有限公司（以下简称"公司"）于 2025 年 6 月 4 日在公 司会议室以现场结合通讯的方式召开了第十届董事会第十三次会议。公司于 2025 年 5 月 23 日以通讯方式发布了召开董事会的通知。出席会议董事应到 5 名，实 到 5 名，分别为邱为碧、陈龙、韦麟福、刘卫、吴良卫。本次会议符合《公司法》 和《公司章程》有关规定，形成的决议合法、有效。 一、审议通过了关于选举公司董事长暨变更法定代表人的议案； 选举邱为碧先生为公司第十届董事会董事长。具体内容详见同日披露的《江 苏四环生物股份有限公司关于选举公司董事长暨变更法定代表人的公告》（公告 编号：临-2025-36号） ...

Investment Rating - The report maintains a "Recommendation" rating for the animal health industry, expecting it to outperform the benchmark index by over 5% in the next 3-6 months [79]. Core Insights - The report highlights significant growth in vaccine approvals for circular, pseudorabies, and diarrhea vaccines, with notable year-on-year increases [7][8]. - The animal drug raw material market shows a continued strong performance in macrolide products, with price indices reflecting a structural differentiation among various products [52][53]. - The overall demand for animal health products is expected to recover, driven by improved profitability in the breeding sector and the introduction of new products [68][69]. Summary by Sections Vaccine Approvals - In April, major vaccine varieties for pigs showed substantial year-on-year growth, with circular vaccine up by 71.2%, pseudorabies vaccine by 73.3%, and diarrhea vaccine by 220% [7][8]. - Cumulative data from January to April indicates most vaccine types experienced significant growth, particularly in pig vaccines, with circular vaccine up by 52.3% and pseudorabies vaccine by 48.2% [8][9]. Raw Material Prices - As of the end of April, the Veterinary Pharmaceutical Index (VPI) was 69.2, reflecting a 5.6% increase from the previous month and a 13.4% increase year-on-year [52][53]. - Prices for macrolide products such as Tylosin, Tylvalosin, and Tilmicosin have shown strong performance, with increases of 10.1%, 17.6%, and 15.4% respectively compared to the end of March [53][54]. Market Outlook - The report anticipates a stable upward trend in the demand for animal health products, supported by a robust breeding sector and ongoing product innovation [68][69]. - The competitive landscape is expected to lead to a dual recovery in performance and valuation for the sector, with a focus on larger companies that can leverage their financial strength and product diversity [69][70]. Investment Recommendations - The report suggests focusing on companies such as Reap Bio, Kexin Bio, and others, which are well-positioned to benefit from the anticipated market recovery [68][70].

证券代码：600201 证券简称：生物股份 公告编号：临2025-033 金宇生物技术股份有限公司关于 以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2024/10/31 | | --- | --- | | 回购方案实施期限 | 董事会审议通过后 12 个月 | | 预计回购金额 | 8,000 万元~16,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 万股 1,538.33 | | 累计已回购股数占总股本比例 | 1.3731% | | 累计已回购金额 | 万元 10,555.22 | | 实际回购价格区间 | 6.37 元/股~7.30 元/股 | 金宇生物技术股份有限公司（以下简称"公司"）于 2024 年 10 月 30 日召开第 十一届董事会第十七次会议，会议审议并通过《关于以集中竞价交易方式回购公司 股份的议案》，同意公 ...

Investment Rating - Industry Rating: Recommended [3] Core Views - The planting industry is seeing significant progress with summer grain wheat harvest, reaching over 30% completion as of May 30, with favorable weather conditions expected to enhance soil moisture and facilitate mechanized sowing [10][11] - The commercialization of genetically modified crops is anticipated to accelerate, aiming to improve yield and self-sufficiency in key varieties, supported by government initiatives to protect new plant varieties [10] - In the pig farming sector, the average price of live pigs is showing a slight increase, with a current price of 14.39 CNY/kg, reflecting a week-on-week rise of 0.36% [11][60] - The supply of breeding sows has slightly decreased, with a total of 40.38 million heads reported, while slaughtering volumes have increased significantly year-on-year [11][60] Summary by Sections Planting Industry - As of May 30, 1.29 million acres of summer wheat have been harvested, with regions like Hubei and Sichuan completing their harvests [10] - The Ministry of Agriculture emphasizes the importance of mechanization to enhance yield and efficiency in sowing [10] - Recommended stocks include Beidahuang and Suqian Agricultural Development for planting, and leading seed companies like Longping High-Tech and Dabeinong for seed production [10] Pig Farming - The average price of external three-way cross pigs is 14.39 CNY/kg, with a slight increase from the previous week [11] - The number of breeding sows has decreased slightly, while slaughtering volumes have increased by 20% year-on-year [11] - Recommended stocks in the breeding sector include Dekang Agriculture, Jinke Smart Agriculture, and Muyuan Foods, with feed companies like Haida Group also highlighted [11] Key Agricultural Products Data Tracking - Corn: Current average price is 2378.15 CNY/ton, with a week-on-week increase of 0.15% [23] - Wheat: Current average price is 2457.51 CNY/ton, with a week-on-week decrease of 0.35% [26] - Soybeans: Current average price is 3927.89 CNY/ton, remaining stable [38] - Cotton: Current average price is 14480.00 CNY/ton, with a slight decrease of 0.14% [42] Feed and Vitamin Prices - The average price of pig feed is 2.71 CNY/kg, showing a week-on-week decrease of 0.73% [48] - Vitamin E is priced at 101.60 CNY/kg, with a decrease of 4.87% [48]

Core Viewpoint - The livestock farming index in China shows a strong upward trend, with specific stocks experiencing significant gains, indicating a positive market sentiment in the livestock sector [1][2]. Group 1: Market Performance - As of June 3, 2025, the China Livestock Farming Index (930707) increased by 1.02%, with notable stock performances including Xiangjia Co., Ltd. (002982) up by 8.30%, Haida Group (002311) up by 2.89%, and Shennong Group (605296) up by 2.75% [1]. - The Livestock ETF (159867) rose by 0.49%, marking a third consecutive increase [1]. Group 2: Price Trends - Recent market data indicates a fluctuating rise in pig prices ahead of the holiday, driven by a reluctance among farming entities to sell at low prices and an increase in slaughterhouse demand due to pre-holiday stocking [1]. - The average weight of pigs sold slightly decreased last week, suggesting a potential shift in market dynamics as the industry prepares for seasonal changes [1]. Group 3: Future Outlook - Short-term projections suggest that rising temperatures may lead to increased weight gain in livestock, but the overall pig price is expected to face downward pressure due to seasonal consumption trends [1]. - In the medium term, a gradual recovery in the national breeding sow inventory is anticipated, with quality pig enterprises likely to achieve unexpected profits through increased sales and reduced costs despite a downward trend in the pig cycle expected in 2025 [1]. Group 4: Index Composition - The top ten weighted stocks in the China Livestock Farming Index (930707) include Haida Group (002311), Muyuan Foods (002714), Wens Foodstuff Group (300498), and others, collectively accounting for 68.9% of the index [2].

Core Viewpoint - The agricultural sector is experiencing a rebound, with the Agricultural ETF from E Fund (562900) showing a significant increase of 2.18% in half a day, leading the industry ETF performance [1][3]. Agricultural Sector Performance - The Agricultural ETF from E Fund (562900) has a half-day trading volume of 694.27 million yuan and a total scale of 0.99 billion units [3]. - Other agricultural ETFs, such as Agricultural 50 ETF (159827) and Agricultural ETF (159825), also showed positive performance with increases of 1.75% and 1.74% respectively [5]. - The Agricultural ETF (159825) has a larger scale of 29.85 billion units and a half-day trading volume of 8529 million yuan [5]. ETF Share Changes - The Agricultural ETF from E Fund (562900) has seen a slight increase in shares this year, with an addition of 11 million units, representing a growth of 12.54% [2]. - The Agricultural ETF (159825) also experienced a share increase of over 10%, adding 474 million units this year [2]. Investment Logic - Domestic grain prices have been rising due to reduced grain imports and drought conditions, indicating a strong demand in the agricultural sector [3]. - Long-term policies focus on food security and improving agricultural productivity, with transgenic biotechnology expected to accelerate under supportive policies [3]. - Upgrades in seed products are anticipated to boost sales and prices for quality seed companies, with leading companies currently valued at a low point, highlighting their long-term investment potential [3]. Major Holdings in Agricultural Indices - The major stocks in the China Modern Agriculture Theme Index include: - Muyuan Foods (002714) with a weight of 14.77% - Wens Foodstuffs Group (300498) with a weight of 14.57% - Haida Group (002311) with a weight of 14.29% [4][6]. - The index reflects companies involved in various agricultural sectors, including animal husbandry, feed, and agricultural machinery [5].

信息披露暂缓与豁免制度 第一章 总 则 金宇生物技术股份有限公司 第一条 为规范金宇生物技术股份有限公司（以下简称"公司"）信息披露暂 缓与豁免行为，确保公司及相关信息披露义务人（以下简称"信息披露义务人"） 依法合规地履行信息披露义务，保护投资者的合法权益，根据《中华人民共和国 公司法》《中华人民共和国证券法》《上市公司信息披露管理办法》《股票上市规 则》以及有关法律、法规、规章和《金宇生物技术股份有限公司章程》（以下简 称"《公司章程》"）、《金宇生物技术股份有限公司信息披露管理制度》的规定， 结合公司信息披露工作的实际情况，制定本制度。 第二条 公司按照《股票上市规则》及交易所其他相关业务规则的规定，办 理信息披露暂缓、豁免业务的，适用本制度。 第三条 公司拟披露的信息存在《股票上市规则》及交易所其他相关业务规 则中规定的可暂缓、豁免披露情形的，由公司自行审慎判断，并接受上海证券交 易所对有关信息披露暂缓、豁免事项的事后监管。 第二章 暂缓、豁免披露信息的范围 第四条 公司和相关信息披露义务人拟披露的信息存在不确定性，属于临时 性商业秘密等情形，及时披露可能损害公司利益或者误导投资者的，可以暂缓披 露。 ...